

Bioasis Technologies Inc. is a multi-asset clinical stage rare and orphan disease company having recently acquired three phase 2 ready programs based on epidermal growth factors for the treatment of Guillain-Barre Syndrome, Optic Neuritis and CIDP. Numerous clinical milestones are projected over the next 6 to 24 months whilst concurrently advancing the extensive capabilities of the xB<sup>3</sup>™ platform for blood-brain barrier therapeutics delivery validated by global life sciences companies. Bioasis will pursue a NASDAQ up listing designed to reach a broader investor base to this undervalued investment opportunity.

## Epidermal Growth Factor (“EGF”)


- Protein that stimulates cell growth and differentiation
- Stimulates oligodendrocyte and Schwann cell differentiation and maturation for remyelination

## Neurodegenerative Disorders

- EGF levels are deficient in neurodegenerative disorders

## EGF Treatment

- Stimulate myelin regeneration
- Protect nerve cells



## Pipeline

Asset	Indication	Drug Discovery	Pre Clinical	Ph-1	Ph-2	Ph-3
<b>Epidermal Growth Factor Platform</b>						
CRES101	Guillain-Barre Syndrome (GBS)	→			Ph-2 initiation Q4, 2022	
CRES101	Optic Neuritis associated with MS	→			Ph-2 initiation Q2, 2023	
CRES101	Chronic Inflammatory Demyelinating Polyneuritis (CIDP)	→				
CRES202	Alzheimer's Disease	→				
<b>xB<sup>3</sup>™ Platform</b>						
xB <sup>3</sup> -008	Hunter Syndrome	→			Ph-1 Initiation Q4, 2023	
xB <sup>3</sup> -007	Gaucher Disease, PD, Lewy Body Dementia	→				
xB <sup>3</sup> -004	Multiple Sclerosis, Epilepsy, Autoinflammatory Diseases	→				
xB <sup>3</sup> -009	CLN, Frontotemporal Dementia ALS	→				

## xB<sup>3</sup> Platform

The Bioasis xB<sup>3</sup>™ patented platform provides researchers with a solution to one of medicine’s most stubborn challenges: how to transport medicines across the blood-brain barrier at doses sufficient to have a therapeutic effect. Scientists at Bioasis have worked for over a decade to develop our proprietary xB<sup>3</sup> platform. Formerly called the Transcend-peptide, xB<sup>3</sup> is based on a human transport protein found circulating at low levels in the blood. The xB<sup>3</sup>™ platform has shown high efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis.

## Corporate Structure

Capitalization (as of August 31, 2022)	Common Stock Equivalents
Common Stock <sup>(1)</sup>	79,414,015
Convertible Notes (convertible @ CAD\$0.31 / share)	9,193,548
Warrants (WAEP CAD\$0.43) <sup>(2)</sup>	22,275,506
Options (WAEP CAD\$0.33)	9,434,690
<b>Total Fully Diluted</b>	<b>120,317,759</b>

- (1) Includes 6.5 million shares issued to owners of Cresence AS in June 2022 as part of the asset purchase agreement  
 (2) 4,839,048 warrants with an exercise price of CAD\$0.41 reset for down round offerings if shares are issued at a price < 95% of the market price

## Contact Us

Deborah Rathjen, Ph.D., Executive Chair & CEO  
[deborah@bioasis.us](mailto:deborah@bioasis.us); +1 203 533 7082  
 Graeme Dick, Colwell Capital Corp.  
[graeme@colwellcapital.com](mailto:graeme@colwellcapital.com); +1 403 561 8989

## Strategic Partners

